Disease Domain | Count |
---|---|
Neoplasms | 5 |
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Monoclonal antibody | 1 |
Target- |
Mechanism Glutamate release inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism A2aR antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EP4 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Nov 2022 |
Sponsor / Collaborator |
Resulting from hit-to-lead optimization, the aminopyrazole
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CVXL-0107 | Parkinson Disease More | Phase 2 |
DT-9081 ( EP4 ) | Advanced Malignant Solid Neoplasm More | Phase 1 |
M-1069 ( A2aR x A2bR ) | Solid tumor More | Phase 1 |
DT-9045 ( PAR-2 ) | Neoplasms More | Preclinical |
Anti-CCR8 antibody(Domain Therapeutics) ( CCR8 ) | Neoplasms More | Preclinical |